Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models

Leukemia Research

Volumn 37, Issue 5, 2013, Pages 510-515

  Duong, Vu H ^a   Lancet, Jeffrey E ^a   Alrawi, Ezzideen ^a   Al Ali, Najla H ^a   Perkins, Janelle ^a   Field, Teresa ^a   Epling Burnette, Pearlie K ^a   Zhang, Ling ^a   List, Alan F ^a   Komrokji, Rami S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Azacitidine; Myelodysplastic syndrome; Therapy related myelodysplastic syndrome; Therapy related myeloid neoplasms

Indexed keywords

AZACITIDINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLOBAL MD ANDERSON RISK MODEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM; SCORING SYSTEM; SURVIVAL PREDICTION; SURVIVAL TIME; THERAPY RELATED MYELOID NEOPLASM; TREATMENT RESPONSE; WHO CLASSIFICATION BASED PROGNOSTIC SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84875892583     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.012     Document Type: Article

References (25)

1. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
2. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
3. Pedersen-Bjergaard J., Andersen M.T., Andersen M.K. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007, 392-397.
4. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100:1542-1551.
5. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
6. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.
7. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
8. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
9. QuintAs-Cardama A., Kim H., Shan J., Jabbour E., Faderl S., Wierda W.G., et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Am Soc Hematol Annu Meet Abstr 2011, 118:967.
10. Itzykson R., Thepot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
11. Fianchi L., Criscuolo M., Lunghi M., Gaidano G., Breccia M., Levis A., et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012, 5:44.
12. Garcia R., Sanz G.F., Llorente DdM, Nomdedeu B., Romero M.M., Bernal T., et al. Clinical experience with azacitidine in secondary myelodysplastic syndrome in Spain. Am Soc Hematol Annu Meet Abstr 2010, 116:1852.
13. Sekeres M.A., Narang M., Komrokji R.S., Maciejewski J.P., List A.F., Street T.K., et al. Therapeutic response to azacitidine (AZA) in patients with secondary myelodysplastic syndromes (sMDS) enrolled in the AVIDA registry. Am Soc Hematol Annu Meet Abstr 2010, 116:2931.
14. Breccia M., Salaroli A., Loglisci G., Martelli M., D'Elia G.M., Nanni M., et al. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leuk Res 2011, 35:1409-1411.
15. D'Alo F., Leone G., Hohaus S., Teofili L., Bozzoli V., Tisi M.C., et al. Response to 5-azacytidine in a patient with relapsed Hodgkin lymphoma and a therapy-related myelodysplastic syndrome. Br J Haematol 2011, 154:141-143.
16. Cheson B.D. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
17. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079.
18. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
19. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
20. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351-1361.
21. Michels S.D., McKenna R.W., Arthur D.C., Brunning R.D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985, 65:1364.
22. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429.
23. Klimek V.M., Dolezal E.K., Tees M.T., Devlin S.M., Stein K., Romero A., et al. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leuk Res 2012, 36:1093-1097.
24. Nardi V., Winkfield K.M., Ok C.Y., Niemierko A., Kluk M.J., Attar E.C., et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012, 30:2340-2347.
25. Litzow M.R., Tarima S., Perez W.S., Bolwell B.J., Cairo M.S., Camitta B.M., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010, 115:1850-1857.